255 related articles for article (PubMed ID: 24664486)
1. Implications of functional proteomics in breast cancer.
Chae YK; Gonzalez-Angulo AM
Oncologist; 2014 Apr; 19(4):328-35. PubMed ID: 24664486
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer proteomics: a review for clinicians.
Galvão ER; Martins LM; Ibiapina JO; Andrade HM; Monte SJ
J Cancer Res Clin Oncol; 2011 Jun; 137(6):915-25. PubMed ID: 21465318
[TBL] [Abstract][Full Text] [Related]
3. Clinical proteomics in breast cancer: a review.
Gast MC; Schellens JH; Beijnen JH
Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
[TBL] [Abstract][Full Text] [Related]
4. SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression.
Zeidan BA; Townsend PA
Breast Cancer Res; 2008; 10(3):107. PubMed ID: 18644101
[TBL] [Abstract][Full Text] [Related]
5. Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression.
Brozkova K; Budinska E; Bouchal P; Hernychova L; Knoflickova D; Valik D; Vyzula R; Vojtesek B; Nenutil R
Breast Cancer Res; 2008; 10(3):R48. PubMed ID: 18510725
[TBL] [Abstract][Full Text] [Related]
6. Proteomics of breast cancer: principles and potential clinical applications.
Bertucci F; Birnbaum D; Goncalves A
Mol Cell Proteomics; 2006 Oct; 5(10):1772-86. PubMed ID: 16733261
[TBL] [Abstract][Full Text] [Related]
7. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors.
Ricolleau G; Charbonnel C; Lodé L; Loussouarn D; Joalland MP; Bogumil R; Jourdain S; Minvielle S; Campone M; Déporte-Fety R; Campion L; Jézéquel P
Proteomics; 2006 Mar; 6(6):1963-75. PubMed ID: 16470659
[TBL] [Abstract][Full Text] [Related]
8. [Proteomics and breast cancer].
Mathelin C; Tomasetto C; Cromer A; Rio MC
Gynecol Obstet Fertil; 2006 Dec; 34(12):1161-9. PubMed ID: 17123853
[TBL] [Abstract][Full Text] [Related]
9. Clinical proteomics and breast cancer.
Zeidan BA; Townsend PA; Garbis SD; Copson E; Cutress RI
Surgeon; 2015 Oct; 13(5):271-8. PubMed ID: 25736469
[TBL] [Abstract][Full Text] [Related]
10. [Proteic profiling SELDI-TOF and breast cancer: clinical potential applications].
Gonçalves A; Bertucci F; Birnbaum D; Borg JP
Med Sci (Paris); 2007 Mar; 23 Spec No 1():23-6. PubMed ID: 17669349
[TBL] [Abstract][Full Text] [Related]
11. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery.
Celis JE; Gromov P; Cabezón T; Moreira JM; Ambartsumian N; Sandelin K; Rank F; Gromova I
Mol Cell Proteomics; 2004 Apr; 3(4):327-44. PubMed ID: 14754989
[TBL] [Abstract][Full Text] [Related]
12. [Application of serum proteomics in breast cancer research].
Zhu ZM; Hu XF; Zeng R
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):561-5. PubMed ID: 18210871
[No Abstract] [Full Text] [Related]
13. Oncoproteomics: Trials and tribulations.
Zhou L; Li Q; Wang J; Huang C; Nice EC
Proteomics Clin Appl; 2016 Apr; 10(4):516-31. PubMed ID: 26518147
[TBL] [Abstract][Full Text] [Related]
14. SELDI-TOF-MS proteomics of breast cancer.
Clarke CH; Buckley JA; Fung ET
Clin Chem Lab Med; 2005; 43(12):1314-20. PubMed ID: 16309366
[TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of serum proteomic patterns in diagnosis of breast cancer].
Liu DH; Zhang LM; Feng WY
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):770-1. PubMed ID: 17366791
[No Abstract] [Full Text] [Related]
16. Proteomic approach to breast cancer.
Laronga C; Drake RR
Cancer Control; 2007 Oct; 14(4):360-8. PubMed ID: 17914336
[TBL] [Abstract][Full Text] [Related]
17. Advanced proteomic technologies for cancer biomarker discovery.
Wong SC; Chan CM; Ma BB; Lam MY; Choi GC; Au TC; Chan AS; Chan AT
Expert Rev Proteomics; 2009 Apr; 6(2):123-34. PubMed ID: 19385940
[TBL] [Abstract][Full Text] [Related]
18. [Surface enhanced laser desorption/ionization (SELDI): proteomics technology and its application in oncology].
Espejel F; Roa JC
Med Clin (Barc); 2008 Sep; 131(8):312-7. PubMed ID: 18803927
[TBL] [Abstract][Full Text] [Related]
19. Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy.
He J; Shen D; Chung DU; Saxton RE; Whitelegge JP; Faull KF; Chang HR
Int J Oncol; 2009 Oct; 35(4):683-92. PubMed ID: 19724903
[TBL] [Abstract][Full Text] [Related]
20. Protein biomarkers for subtyping breast cancer and implications for future research.
Mueller C; Haymond A; Davis JB; Williams A; Espina V
Expert Rev Proteomics; 2018 Feb; 15(2):131-152. PubMed ID: 29271260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
